The PedMAb protocol has been accepted for publication in the BMC Infectious Diseases under the title:
“Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial Acronym: PedMAb1“